Development of a novel bivalent baculovirus vectors for complement resistance and sustained transgene expression and its application in anti-angiogenesis gene therapy

Wang, Zhisheng; Mengting, Li; Ji, Yonggan; Yang, Minsheng; Yang, Wen; Wang, Jinbao; Li, Wei

doi:10.1016/j.biopha.2019.109765

Cited by 6 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It showed a prominent inhibitor effect on tumor growth in hepatocellular carcinoma and prolonged the life spans of mice significantly. 62 In the last two decades, several antiangiogenic monoclonal anti- for the treatment of gastric cancer in the future. 64 The antitumoral effect of an angiostatic drug is closely related to several factors.…”

Section: Antiangiogenic Gene Therapymentioning

confidence: 99%

See 1 more Smart Citation

Gene therapy in cancer

Cesur‐Ergün,

Demir‐Dora

2023

The Journal of Gene Medicine

View full text Add to dashboard Cite

Gene therapy, recently frequently investigated, is an alternative treatment method that introduces therapeutic genes into a cancer cell or tissue to cause cell death or slow down the growth of the cancer. This treatment has various strategies such as therapeutic gene activation or silencing of unwanted or defective genes; therefore a wide variety of genes and viral or nonviral vectors are being used in studies. Gene therapy strategies in cancer can be classified as inhibition of oncogene activation, activation of tumor suppressor gene, immunotherapy, suicide gene therapy and antiangiogenic gene therapy. In this review, we explain gene therapy, gene therapy strategies in cancer, approved gene medicines for cancer treatment and future of gene therapy in cancer. Today gene therapy has not yet reached the level of replacing conventional therapies. However, with a better understanding of the mechanism of cancer to determine the right treatment and target, in the future gene therapy, used as monotherapy or in combination with another existing treatment options, is likely to be used as a new medical procedure that will make cancer a controllable disease.

show abstract

Section: Antiangiogenic Gene Therapymentioning

confidence: 99%

“…Compared with control groups, it was found to increase human endostatin and angiostatin expression with significantly higher antiangiogenic activity. It showed a prominent inhibitor effect on tumor growth in hepatocellular carcinoma and prolonged the life spans of mice significantly 62 …”

Section: Introductionmentioning

confidence: 99%

Gene therapy in cancer

Cesur‐Ergün,

Demir‐Dora

2023

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

“…Baculovirus expression vectors, which were initially used for recombinant protein expression, have the potential to serve as the vectors for gene therapy, as they can carry up to 38 kb DNA inserts and transfect various cell types without evoking immune responses in humans and without the risk of insertional mutagenesis. However, the major drawbacks of the vectors are the limited expression duration of the transgene, the requirement of entry through the basolateral membrane, and the rapid virus inactivation by serum complements, which should be further studied to optimize ( Hu, 2006 ; Wang et al, 2020 ).…”

Section: Gene Delivery Systemsmentioning

confidence: 99%

Genes in pediatric pulmonary arterial hypertension and the most promising BMPR2 gene therapy

Dai

2022

Front. Genet.

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) is a rare but progressive and lethal vascular disease of diverse etiologies, mainly caused by proliferation of endothelial cells, smooth muscle cells in the pulmonary artery, and fibroblasts, which ultimately leads to right-heart hypertrophy and cardiac failure. Recent genetic studies of childhood-onset PAH report that there is a greater genetic burden in children than in adults. Since the first-identified pathogenic gene of PAH, BMPR2, which encodes bone morphogenetic protein receptor 2, a receptor in the transforming growth factor-β superfamily, was discovered, novel causal genes have been identified and substantially sharpened our insights into the molecular genetics of childhood-onset PAH. Currently, some newly identified deleterious genetic variants in additional genes implicated in childhood-onset PAH, such as potassium channels (KCNK3) and transcription factors (TBX4 and SOX17), have been reported and have greatly updated our understanding of the disease mechanism. In this review, we summarized and discussed the advances of genetic variants underlying childhood-onset PAH susceptibility and potential mechanism, and the most promising BMPR2 gene therapy and gene delivery approaches to treat childhood-onset PAH in the future.

show abstract

“…75 More recently, Wang et al generated a bivalent hybrid baculovirus that displayed DAF and eGFP mediated by SB transposon system which prolonged the expression of hEA genes to 90 days. 76 Moreover, the hEA genes exhibited antitumor effects in hepatocellular carcinoma xenograft mouse models as well as complement resistance. 76 Alternatively, two baculovirus vectors have been used to generate a self-replicative episome providing constant gene expression for 48 days.…”

mentioning

confidence: 99%

“…76 Moreover, the hEA genes exhibited antitumor effects in hepatocellular carcinoma xenograft mouse models as well as complement resistance. 76 Alternatively, two baculovirus vectors have been used to generate a self-replicative episome providing constant gene expression for 48 days. 77 Here, one vector encoding flippase recombinase cleaves and activates the other encoding oriP/EBNA1 from EBV and gene of interest within the Frt flanking region.…”

mentioning

confidence: 99%

Baculoviruses in Gene Therapy and Personalized Medicine

Schaly¹,

Ghebretatios²,

Prakash³

2021

BTT

View full text Add to dashboard Cite

This review will outline the role of baculoviruses in gene therapy and future potential in personalized medicine. Baculoviruses are a safe, non-toxic, non-integrative vector with a large cloning capacity. Baculoviruses are also a highly adaptable, low-cost vector with a broad tissue and host tropism due to their ability to infect both quiescent and proliferating cells. Moreover, they only replicate in insect cells, not mammalian cells, improving their biosafety. The beneficial properties of baculoviruses make it an attractive option for gene delivery. The use of baculoviruses in gene therapy has advanced significantly, contributing to vaccine production, anti-cancer therapies and regenerative medicine. Currently, baculoviruses are primarily used for recombinant protein production and vaccines. This review will also discuss methods to optimize baculoviruses protein production and mammalian cell entry, limitations and potential for gene therapy and personalized medicine. Limitations such as transient gene expression, complement activation and virus fragility are discussed in details as they can be overcome through further genetic modifications and other methods. This review concludes that baculoviruses are an excllent candidate for gene therapy, personalized medicine and other biotherapeutic applications.

show abstract

Development of a novel bivalent baculovirus vectors for complement resistance and sustained transgene expression and its application in anti-angiogenesis gene therapy

Cited by 6 publications

References 40 publications

Gene therapy in cancer

Gene therapy in cancer

Genes in pediatric pulmonary arterial hypertension and the most promising BMPR2 gene therapy

Baculoviruses in Gene Therapy and Personalized Medicine

Contact Info

Product

Resources

About